I learned I was HIV-positive in 1995. At the time, I was in a committed relationship with a man I thought I was going to marry. Then he got sick. He kept coughing. He told me it was just a cold or the flu. But he went into the hospital, and they quarantined him. When I went to visit him in the hospital, I ran into one of my friends, who worked there. In a small...
AIDS Research Alliance is pleased to announce that it will serve as an investigative site for a new Phase I Interaction Study examining interactions between HIV treatment Isentress (Raltegravir) and over-the-counter (OTC) antacids.
Isentress, approved by the FDA in 2007, is the only drug in its class of integrase inhibitors. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the DNA...
Members of our Community Education and Recruitment team—Caleigh Douglass and James Aboagye, along with our Medical Director, Dr. Stephen Brown, attended the HIV Vaccine Trials Network (HVTN) Full Group Meeting in Washington, D.C. earlier this month.
At the conference, staff from the U.S. and global HVTN sites gathered to discuss progress being made in HIV vaccine research, as well as outreach strategies for recruiting trial volunteers.
Looking for a great Father’s Day gift? We’ve put together a gift guide for every type of dad – from the “Golf Pro” to the “Gadget Guy.” The best part of all is that each purchase earns AIDS Research Alliance a donation—at no extra charge to you.
Last week, FDA advisers recommended approval of the drug Truvada to prevent HIV transmission. This is, in many respects, a momentous step in the fight on HIV/AIDS. But Truvada’s approval would not diminish the pressing need for an HIV vaccine.
Truvada has been shown to reduce risk of infection by up to 42%* in gay and bisexual men, and up to 75% in heterosexual couples where one partner is HIV-positive.
Page 12 of 15 pages ‹ First < 10 11 12 13 14 > Last ›